Key result
High pre-LVAD cell-free DNA is linked to ~3-fold worse infection-free survival.
Why the study?
Do plasma cell-free DNA levels reflect end-organ injury and predict post-implantation outcomes in patients with advanced heart failure undergoing LVAD implantation?
Cohort (n=308)
Yes
Do plasma cell-free DNA levels reflect end-organ injury and predict post-implantation outcomes in patients with advanced heart failure undergoing LVAD implantation?
Hazard Ratio: 2.94 (95% CI 1.31–6.56)
p-value: p=0.006
Plasma cell-free DNA levels are elevated in advanced heart failure, decrease following LVAD implantation, and high pre-LVAD levels strongly predict post-LVAD infections and hemocompatibility-related adverse events.
BACKGROUND: Adverse events after durable left ventricular assist devices (LVADs) pose a challenge to survival. However, there are limited risk stratification approaches. Plasma cell-free DNA (cfDNA) offers potential as a biomarker for assessing end-organ injury and risk stratification. METHODS: The study included a multicenter prospective cohort of patients with heart failure with and without LVAD (cohort 1), a separate cohort of patients with heart failure with paired samples before and after LVAD (cohort 2) implantation, and a comparator group of healthy controls. Nuclear cfDNA (ncfDNA) and mitochondrial cfDNA were quantified by digital droplet polymerase chain reaction. Tissue-specific cfDNA was identified using whole-genome bisulfite sequencing. Differences in cfDNA levels by LVAD use were assessed with the Wilcoxon rank-sum test or the paired t test. Outcomes (hemocompatibility-related adverse event–free survival and infection-free survival) by cfDNA tertiles were compared by log-rank tests. RESULTS: Cohort 1 had 76 patients with LVAD and 144 without LVAD. Cohort 2 had 40 patients with LVAD with samples before and after LVAD. ncfDNA levels were 4-fold higher (9794 versus 2386 copies/mL; P <0.001), and mtDNA was 1.5-fold higher (134 707 versus 82 054 copies/mL; P =0.01) in cohort 1 compared with healthy controls (n=48). Patients without LVAD had higher ncfDNA levels compared with those with LVAD in cohort 1 (11 423 versus 7912 copies/mL; P =0.019). After LVAD placement in cohort 2, ncfDNA nearly halved (18 980 versus 10 228 copies/mL; P <0.001), with significant reductions in innate immune, vascular endothelium, gastrointestinal, and liver cfDNA levels. The highest pre-LVAD tertile of ncfDNA was associated with worse infection-free (HR, 2.94 [95% CI, 1.31–6.56]; P =0.006) and hemocompatibility-related adverse event–free (HR, 3.24 [95% CI, 1.03–10.3]; P =0.034) survival. CONCLUSIONS: LVAD implantation was associated with reductions in systemic and tissue-specific cfDNA levels. cfDNA levels offer promise for improving risk stratification of LVAD candidates for post-LVAD outcomes.
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) conducted a cohort in Advanced Heart Failure (n=308). Highest pre-LVAD tertile of ncfDNA vs. Lower tertiles of ncfDNA was evaluated on Infection-free survival (HR 2.94, 95% CI 1.31-6.56, p=0.006). The highest pre-LVAD tertile of nuclear cell-free DNA was associated with worse infection-free (HR 2.94; 95% CI 1.31-6.56; P=0.006) and hemocompatibility-related adverse event-free survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: